Table 1.
Drug name | Target | Disease or model | Stage | Reference |
---|---|---|---|---|
SCH 527123 | CXCR2 | Severe asthma, allergen-induced asthma, COPD, psoriasis and colon cancer | Phase I–II | 185 |
Reparixin | CXCR1 and CXCR2 | Ischemia-reperfusion injury; lung, pancreatic islet and kidney transplantation, and breast cancer | Phase II–III | 186 |
DF 2156A | CXCR1 and CXCR2 | Active bullous pemphigoid | Phase II | - |
AZD-8309 | CXCR1 and CXCR2 | LPS-induced airway inflammation | Phase I | 187 |
SB-656933 | CXCR2 | Ulcerative colitis, cystic fibrosis and ozone airway inflammation | Phase I–II | 132 |
GSK1325756 | CXCR2 | Influenza virus infection and healthy volunteers | Phase II | 188 |
AZD5069 | CXCR2 | Healthy volunteers and LPS-induced airway inflammation | Phase I |
189 190 |
QBM076 | Not known | COPD | Phase II | - |
COPD, chronic obstructive pulmonary disease; CXCR, CXC-chemokine receptor; LPS, lipopolysaccharide. More details at clinicaltrials.gov.